Sarah B. Mulkey

Dr. Sarah B. Mulkey

1. Prenatal Pediatrics Institute, Children’s National Hospital, Washington, DC 20010, USA
+2
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Pediatrics
Verified
Journal Article
Closed access
PDF file
YWYvonne W. Wu
Yvonne W. Wu
AMAmit M. Mathur
Amit M. Mathur
TCTaeun Chang
Taeun Chang
RMRobert C. McKinstry
Robert C. McKinstry
SMSarah B. Mulkey
Sarah B. Mulkey
RBRoberta A. Ballard
Roberta A. Ballard
OBJECTIVE: To determine if multiple doses of erythropoietin (Epo) administered with hypothermia improve neuroradiographic and short-term outcomes of newborns with hypoxic-ischemic encephalopathy. METHODS: In a phase II double-blinded, placebo-controlled trial, we randomized newborns to receive Epo (1000 U/kg intravenously; n = 24) or placebo (n = 26) at 1, 2, 3, 5, and 7 days of age. All infants had moderate/severe encephalopathy; perinatal depression (10 minute Apgar <5, pH <7.00 or base deficit ≥15, or resuscitation at 10 minutes); and received hypothermia. Primary outcome was neurodevelopment at 12 months assessed by the Alberta Infant Motor Scale and Warner Initial Developmental Evaluation. Two independent observers rated MRI brain injury severity by using an established scoring system. RESULTS: The mean age at first study drug was 16.5 hours (SD, 5.9). Neonatal deaths did not significantly differ between Epo and placebo groups (8% vs 19%, P = .42). Brain MRI at mean 5.1 days (SD, 2.3) showed a lower global brain injury score in Epo-treated infants (median, 2 vs 11, P = .01). Moderate/severe brain injury (4% vs 44%, P = .002), subcortical (30% vs 68%, P = .02), and cerebellar injury (0% vs 20%, P = .05) were less frequent in the Epo than placebo group. At mean age 12.7 months (SD, 0.9), motor performance in Epo-treated (n = 21) versus placebo-treated (n = 20) infants were as follows: Alberta Infant Motor Scale (53.2 vs 42.8, P = .03); Warner Initial Developmental Evaluation (28.6 vs 23.8, P = .05). CONCLUSIONS: High doses of Epo given with hypothermia for hypoxic-ischemic encephalopathy may result in less MRI brain injury and improved 1-year motor function.

1 March 2020 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
SMSarah B. Mulkey
Sarah B. Mulkey
MAMargarita Arroyave-Wessel
Margarita Arroyave-Wessel
CPColleen Peyton
Colleen Peyton
DBDorothy I. Bulas
Dorothy I. Bulas
YFYamil Fourzali
Yamil Fourzali
CCCarlos Cure
Carlos Cure
Infants who were exposed in utero to Zika virus (ZIKV) during the epidemic of 2015 to 2016 in Central and South America have aged into early childhood. Currently, there is a need to understand the spectrum of neurodevelopmental outcomes in children with congenital ZIKV exposure and to provide appropriate follow-up and neurodevelopmental interventions to at-risk children. Quiz Ref ID Outcomes are poor in infants with severe neurologic abnormalities associated with congenital Zika syndrome (CZS), which includes microcephaly, global neurodevelopmental delay, epilepsy, visual impairment, and deafness.1,2 However, most newborns with prenatal ZIKV exposure do not have clinical manifestations of CZS.3 The risk and spectrum of neurodevelopmental impairment in infants without CZS after exposure to prenatal ZIKV are not yet known but are of major importance given the large number of children exposed to ZIKV without apparent neurologic abnormalities at birth.

30 August 2018 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
SMSarah B. Mulkey
Sarah B. Mulkey
APAdre J. du Plessis
Adre J. du Plessis

26 November 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
TSTristan T. Sands
Tristan T. Sands
MBMartina Balestri
Martina Balestri
GBGiulia Bellini
Giulia Bellini
SMSarah B. Mulkey
Sarah B. Mulkey
ODOlivier Danhaive
Olivier Danhaive
MCMaria Roberta Cilio
Maria Roberta Cilio

31 January 2017 in Epilepsia
Verified
Journal Article
Open access
PDF file
SMSarah B. Mulkey
Sarah B. Mulkey
BBBruria Ben‐Zeev
Bruria Ben‐Zeev
JNJoost Nicolai
Joost Nicolai
JCJohn L. Carroll
John L. Carroll
SGSabine Grønborg
Sabine Grønborg
MCMaria Roberta Cilio
Maria Roberta Cilio
Summary: Objective: To analyze whether KCNQ2 R201C and R201H variants, which show atypical gain‐of‐function electrophysiologic properties in vitro, have a distinct clinical presentation and outcome.Methods: Ten children with heterozygous, de novo KCNQ2 R201C or R201H variants were identified worldwide, using an institutional review board (IRB)–approved KCNQ2 patient registry and database. We reviewed medical records and, where possible, interviewed parents and treating physicians using a structured, detailed phenotype inventory focusing on the neonatal presentation and subsequent course.Results: Nine patients had encephalopathy from birth and presented with prominent startle‐like myoclonus, which could be triggered by sound or touch. In seven patients, electroencephalography (EEG) was performed in the neonatal period and showed a burst‐suppression pattern. However, myoclonus did not have an EEG correlate. In many patients the paroxysmal movements were misdiagnosed as seizures. Seven patients developed epileptic spasms in infancy. In all patients, EEG showed a slow background and multifocal epileptiform discharges later in life. Other prominent features included respiratory dysfunction (perinatal respiratory failure and/or chronic hypoventilation), hypomyelination, reduced brain volume, and profound developmental delay. One patient had a later onset, and sequencing indicated that a low abundance (~20%) R201C variant had arisen by postzygotic mosaicism.Significance: Heterozygous KCNQ2 R201C and R201H gain‐of‐function variants present with profound neonatal encephalopathy in the absence of neonatal seizures. Neonates present with nonepileptic myoclonus that is often misdiagnosed and treated as seizures. Prognosis is poor. This clinical presentation is distinct from the phenotype associated with loss‐of‐function variants, supporting the value of in vitro functional screening. These findings suggest that gain‐of‐function and loss‐of‐function variants need different targeted therapeutic approaches.

1 December 2018 in Seminars in Pediatric Neurology
Verified
Journal Article
Closed access
SMSarah B. Mulkey
Sarah B. Mulkey
APAdre Dú Plessis
Adre Dú Plessis